RPA2 and neoplasm: In multiple endocrine neoplasia type 1, numerous mutations have been reported in MEN1 gene that was known to disrupt the interaction of menin to RPA2 without affecting its binding to other factors such as Jun D. Previous studies on P12L, F144V and W183S mutations of RPA2 binding regions raise the possibility that RPA2 is important for the tumor suppressor activity of menin21.